Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letaplimab in advanced malignant tumors and lymphomas
NCT03763149Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Feb 2019
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of letaplimab in Advanced Malignant Solid Neoplasm (AMSN) and lymphoma, sponsored by Innovent Biologics. Primary endpoint: Adverse Events at 2 years. Started Feb 2019; status: completed.
02
Drugs
letaplimab
03
Conditions
Advanced Malignant Solid Neoplasm (AMSN)lymphoma
Beyond the preview
Go deeper on NCT03763149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03763149.